Odanacatib: Difference between revisions
m clean up- spelling of "et al." using AWB |
Anypodetos (talk | contribs) No ATC code |
||
| Line 5: | Line 5: | ||
| CAS_number = 603139-19-1 |
| CAS_number = 603139-19-1 |
||
| CAS_supplemental = |
| CAS_supplemental = |
||
| ATC_prefix = |
| ATC_prefix = none |
||
| ATC_suffix = |
| ATC_suffix = |
||
| ATC_supplemental = |
| ATC_supplemental = |
||
Revision as of 09:57, 31 July 2009
{{Drugbox | IUPAC_name = N-(1-cyanocyclopropyl)-4-fluoro-N2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)biphenyl-4-yl]ethyl}-L-leucinamide | synonyms = (2S)-N-(1-cyanocyclopropyl)-4-fluoro-4-methyl-2-{[(1S)-2,2,2-trifluoro-1-{4'-(methanesulfonyl)-[1,1'-biphenyl]-4-yl}ethyl]amino}pentanamide | image = Odanacatib.png | CAS_number = 603139-19-1 | CAS_supplemental = | ATC_prefix = none | ATC_suffix = | ATC_supplemental = | PubChem = | DrugBank = | chemical_formula = | C=25 | H=27 | F=4 | N=3 | O=3 | S=1 | molecular_weight = 525.56 g/mol | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = }} Odanacatib (pINN; codenamed MK-0822) is an investigational treatment for osteoporosis. It is an inhibitor of cathepsin K,[1] an enzyme involved in bone resorption.
It is being developed by Merck & Co. As of May 2008, Merck is conducting phase III clinical trials.
References
- ^ Gauthier JY, Chauret N, Cromlish W; et al. (2008). "The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K". Bioorg. Med. Chem. Lett. 18 (3): 923–8. doi:10.1016/j.bmcl.2007.12.047. PMID 18226527.
{{cite journal}}: Explicit use of et al. in:|author=(help); Unknown parameter|month=ignored (help)CS1 maint: multiple names: authors list (link)
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |